Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients

Clinical and Diagnostic Laboratory Immunology

Volumn 6, Issue 6, 1999, Pages 808-811

  Baqui, A A M A ^a   Meiller, Timothy F ^a   Falkler Jr , William A ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN SECRETION; SALIVA LEVEL; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 0032754941     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.6.6.808-811.1999     Document Type: Article

References (19)

1. Archibald, D. W., and G. A. Cole. 1990. In vitro inhibition of HIV-1 infectivity by human salivas. AIDS Res. Hum. Retroviruses 6:1425-1432.
2. Bergey, E. J., M.-I. Cho, M.-L. Hammarskjold, D. Rekosh, M. J. Levine, B. M. Blumberg, and L. G. Epstein. 1993. Aggregation of human immunodeficiency virus type 1 by human salivary secretions. Crit. Rev. Oral Biol. Med. 4:467-473.
3. Coppenhaver, D. H., P. Sriyuktasuth-Woo, S. Baron, C. E. Barr, and M. N. Qureshi. 1994. Correlation of nonspecific antiviral activity with the ability to isolate infectious HIV-1 from saliva. N. Engl. J. Med. 330:1314-1315.
4. Fox, P. C., A. Wolff, C.-K. Yeh, J. C. Atkinson, and B. J. Baum. 1988. Saliva inhibits HIV-1 infectivity. J. Am. Dent. Assoc. 116:635-637.
5. Fox, P. C., A. Wolff, C.-K. Yeh, J. C. Atkinson, and B. J. Baum. 1989. Salivary inhibition of HIV-1 infectivity: functional properties and distribution in men. women and children. J. Am. Dent. Assoc. 118:709-711.
6. Friedland, G. H., B. R. Saltzman, M. F. Rogers, P. A. Kahl, M. L. Lesser, M. M. Meyers, and R. S. Klein. 1986. Lack of household transmission of HTLV-III infection. N. Engl. J. Med. 314:344-349.
7. Fultz, P. N. 1986. Components of saliva inactivate human immunodeficiency virus. Lancet ii:1215.
8. Gerberding, J. L., C. E. Bryant-LeBlanc, K. Nelson, A. R. Moss, D. Osmond, H. F. Chambers, J. R. Carlson, W. L. Drew, J. A. Levy, and M. A. Sand. 1987. Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS related conditions. J. Infect. Dis. 156:1-8.
9. Klein, R. S., J. A. Phelan, P. H. Freeman, M. S. Schable, G. H. Friedland, N. Trieger, and N. H. Steigbigel. 1988. Low occupational risk of human immunodeficiency virus infection among dental professionals. N. Engl. J. Med. 318:86-90.
10. Kramps, J. A., C. Franken, and J. H. Dijkman. 1988. Quantity of antileucoprotease relative to alpha-1 proteinase inhibitor in peripheral air spaces of the human lung. Clin. Sci. 75:351-353.
11. Malamud, D., C. Davis, P. Berthold, E. Roth, and H. Friedman. 1993. Human submandibular saliva aggregates HIV. AIDS Res. Hum. Retroviruses 9:633-637.
12. Masuda, K.-I., T. Suga, A. Takeuchi, M. Kanesaki, A. Imaizumi, and Y. Suzuki. 1994. Specific cleavage of secretory leukocyte protease inhibitor by neutrophil elastase and saliva. Biochem. Pharmacol. 48:651-657.
13. McNeely, T. B., M. Dealy, D. J. Dripps, J. M. Orenstein, S. P. Eisenberg, and S. M. Wahl. 1995. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J. Clin. Investig. 96:456-464.
14. McNeely, T. B., D. C. Shugars, M. Rosendahl, C. Tucker, S. P. Eisenberg, and S. M. Wahl. 1997. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90:1141-1149.
15. Mellors, J. W., L. A. Kingsley, C. R. Rinaldo, J. A. Todd, B. S. Hoo, R. P. Kokka, and P. Gupta. 1995. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122:573-579.
16. Moore, B. E., C. M. Flaitz, D. H. Coppenhaver, C. M. Nichols, G. D. Kalmaz, J. D. Bessman, M. W. Cloyd, D. P. Lynch, B. S. Prabhakar, and S. Baron. 1993. HIV recovery from saliva before and after dental treatment: inhibitors may have critical role in viral inactivation. J. Am. Dent. Assoc. 124:67-74.
17. Rovinovitch, M. R., J. M. Iversen, and L. Resnick. 1993. Anti-intectivity activity of human salivary secretions toward human immunodeficiency virus. Crit. Rev. Oral Biol. Med. 4:455-459.
18. Sallenave, J.-M., M. S.-T. Har, G. Cox, M. Chignard, and J. Gauldie. 1997 Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J. Leukoc. Biol. 61:695-702.
19. Yeh, C.-K., B. Handleman, P. C. Fox, and B. Baum. 1992. Further studies of salivary inhibition of HIV-1 infectivity. J. Acquir. Immune Defic. Syndr. 9:898-903.